All In Biotech

Drug Trial Radar · NCT03374475

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Jan 5, 2018

Primary completion

Apr 29, 2019

Study completion Apr 29, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 \[HDRS17\], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 \[HAM-D6\]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale \[RRS\], Sleep and Worry visual analogue scale \[VAS\], quantitative electro-encephalography \[qEEG\], heart rate variability \[HRV\] and others).

Conditions

  • Depressive Disorder, Major

Interventions

  • JNJ-42847922 20mgDrug

    Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.

  • JNJ-42847922 40mgDrug

    Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.

  • PlaceboDrug

    All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Total ScoreTime frame: Baseline up to Day 57
  2. Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Sleep Item-Adjusted Total ScoreTime frame: Baseline up to Day 57
  3. Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Anxiety/Somatization Factor ScoreTime frame: Baseline up to Day 57
  4. Change From Baseline in 6 Item Subscale From HDRS17 (HAM-D6) ScoreTime frame: Baseline up to Day 57

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Artemis Institute for Clinical Research

    San Diego, California

  • Artemis Institute for Clinical Research

    San Marcos, California

  • Qps-Mra, Llc

    Miami, Florida

  • SGS Phase 1 Unit AZ St-Maarten

    Mechelen, Belgium

  • Clinical Pharmacology Unit

    Merksem, Belgium

  • Charite Research Organisation GmbH

    Berlin, Germany

  • Emovis GmbH

    Berlin, Germany

  • Fraunhofer-Institut für Toxikologie und Experimentelle Medizin

    Hanover, Germany

  • Somni Bene GmbH

    Schwerin, Germany

  • Centre for Human Drug Research

    Leiden, Netherlands

  • MAC Clinical Research

    Blackpool, United Kingdom

  • MAC Clinical Research

    Liverpool, United Kingdom

  • Hammersmith Medicines Research

    London, United Kingdom

  • MAC Clinical Research

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.